|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...2122232425262728293031...4041» |
- Trial completion: Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients (clinicaltrials.gov) - Feb 11, 2014
P4, N=36, Completed, Sponsor: Tehran University of Medical Sciences
Enrolling by invitation --> Completed
- ||| glatiramer acetate / Generic mfg.
Enrollment open: GAO: Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months (clinicaltrials.gov) - Feb 10, 2014
P=N/A, N=100, Recruiting, Sponsor: University at Buffalo
Enrolling by invitation --> Completed Not yet recruiting --> Recruiting
- hydroxyurea / Generic mfg.
Trial termination: Hydroxyurea in Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Feb 9, 2014
P2/3, N=33, Terminated, Sponsor: S. Andrea Hospital
Not yet recruiting --> Recruiting Recruiting --> Terminated; No efficacy (interim.analysis)
- Trial termination: FLORIMS: Flupirtine as Oral Treatment in Multiple Sclerosis (clinicaltrials.gov) - Feb 9, 2014
P2, N=30, Terminated, Sponsor: Charite University, Berlin, Germany
Recruiting --> Terminated; No efficacy (interim.analysis) Completed --> Terminated
- hydroxyurea / Generic mfg.
Enrollment change: Hydroxyurea in Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Feb 9, 2014
P2/3, N=33, Terminated, Sponsor: S. Andrea Hospital
Completed --> Terminated N=60 --> 33
- | Trial completion: Interferon ß-1b Treatment by Cyclical Administration (clinicaltrials.gov) - Feb 9, 2014
P2/3, N=60, Completed, Sponsor: S. Andrea Hospital
N=60 --> 33 Active, not recruiting --> Completed
- New P1/2 trial, Immunomodulating: IMODALS: Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 (clinicaltrials.gov) - Feb 9, 2014
P1/2, N=24, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
- Trial completion: Rehabilitation in Multiple Sclerosis: Influence of Exercise on Development of Insulin Resistance, Muscle Power and Aerobic Capacity (clinicaltrials.gov) - Feb 6, 2014
P=N/A, N=45, Completed, Sponsor: Hasselt University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NurOwn (MSC-NTF) / BrainStorm Cell Therap
Enrollment closed, Stroma: Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Feb 3, 2014
P2a, N=14, Active, not recruiting, Sponsor: Hadassah Medical Organization
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Rebif (human IFN-β-1a) / EMD Serono
Enrollment change: EMR200136_550: Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=515, Active, not recruiting, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting N=346 --> 515
- Enrollment change: Group Balance Training for People With Multiple Sclerosis (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=87, Completed, Sponsor: Örebro County Council
N=346 --> 515 N=70 --> 87
- ||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment change: CHOLINE: A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (clinicaltrials.gov) - Feb 2, 2014
P2, N=129, Active, not recruiting, Sponsor: Merck KGaA
N=70 --> 87 N=250 --> 129
- || Rebif (human IFN-β-1a) / EMD Serono
Enrollment closed: EMR200136_550: Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=515, Active, not recruiting, Sponsor: Merck KGaA
N=250 --> 129 Recruiting --> Active, not recruiting
- ||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment closed: CHOLINE: A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly (clinicaltrials.gov) - Feb 2, 2014
P2, N=129, Active, not recruiting, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: Group Balance Training for People With Multiple Sclerosis (clinicaltrials.gov) - Feb 2, 2014
P=N/A, N=87, Completed, Sponsor: Örebro County Council
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial initiation date: EMR200136-549: Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (clinicaltrials.gov) - Jan 30, 2014
P2, N=80, Recruiting, Sponsor: Merck KGaA
Recruiting --> Completed Initiation date: Oct 2011 --> Apr 2012
- || Rebif (human IFN-?-1a) / EMD Serono
Trial initiation date, HEOR: MusiClock: An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) (clinicaltrials.gov) - Jan 30, 2014
P=N/A, N=65, Completed, Sponsor: Merck KGaA
Initiation date: Oct 2011 --> Apr 2012 Initiation date: Nov 2009 --> Nov 2010
- ||| Rebif (human IFN-?-1a) / EMD Serono
Trial completion, HEOR: MusiClock: An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) (clinicaltrials.gov) - Jan 30, 2014
P=N/A, N=65, Completed, Sponsor: Merck KGaA
Initiation date: Nov 2009 --> Nov 2010 Active, not recruiting --> Completed
- Enrollment open: T and B Cell Responses in Autoimmune Diseases (clinicaltrials.gov) - Jan 29, 2014
P=N/A, N=280, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- sildenafil / Generic mfg.
New P2/3 trial: PROFIL: "As Required" Oral Sildenafil in Raynaud's Phenomenon (clinicaltrials.gov) - Jan 28, 2014
P2/3, N=42, Recruiting, Sponsor: University Hospital, Grenoble
- New P4 trial: ANSG: Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS (clinicaltrials.gov) - Jan 27, 2014
P4, N=30, Recruiting, Sponsor: Jochen Vehoff
- | Tysabri (natalizumab) / Biogen, Royalty
Trial completion: NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness (clinicaltrials.gov) - Jan 27, 2014
P4, N=37, Completed, Sponsor: Cornerstone Health Care, PA
Not yet recruiting --> Recruiting Recruiting --> Completed
- | glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Jan 27, 2014
P1, N=18, Recruiting, Sponsor: to-BBB technologies B.V.
- |||||| Circadin (melatonin prolonged release) / Lundbeck, Neurim, Flynn Pharma, Grupo Insud, Biocodex, Kuhnil Pharma
Enrollment open: Efficacy and Safety of Circadin (clinicaltrials.gov) - Jan 27, 2014
P3, N=120, Recruiting, Sponsor: Neurim Pharmaceuticals Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- | teriflunomide / Generic mfg.
New P1 trial: A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - Jan 26, 2014
P1, N=12, Not yet recruiting, Sponsor: Sanofi
- ||| Tysabri (natalizumab) / Biogen, Royalty
Enrollment open: STRATIFY-2: JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (clinicaltrials.gov) - Jan 23, 2014
P=N/A, N=8000, Enrolling by invitation, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Active, not recruiting --> Enrolling by invitation
- ||| ZB-168 / Zura Bio
New P1 trial: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jan 23, 2014
P1, N=60, Not yet recruiting, Sponsor: Pfizer
- Lemtrada (alemtuzumab) / Sanofi
Enrollment change, Metastases: Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 22, 2014
P4, N=8, Enrolling by invitation, Sponsor: University of Chicago
Active, not recruiting --> Enrolling by invitation N=10 --> 8
- || Myrbetriq (mirabegron) / Astellas
New P2/3 trial: Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients (clinicaltrials.gov) - Jan 22, 2014
P2/3, N=72, Not yet recruiting, Sponsor: Lawson Health Research Institute
- ozanezumab (GSK 1223249) / GSK
Enrollment closed: Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Jan 22, 2014
P2, N=294, Active, not recruiting, Sponsor: GlaxoSmithKline
N=10 --> 8 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment open: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Jan 21, 2014
P2, N=10, Recruiting, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Tysabri (natalizumab) / Biogen, Royalty, Betaseron (IFN-?-1b) / Bayer
Trial termination: Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 20, 2014
P4, N=5, Terminated, Sponsor: Claudio Gobbi
Not yet recruiting --> Recruiting Recruiting --> Terminated; Problems to recruit the needed number of patients in the planned time
- Tysabri (natalizumab) / Biogen, Royalty, Betaseron (IFN-?-1b) / Bayer
Enrollment change: Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 20, 2014
P4, N=5, Terminated, Sponsor: Claudio Gobbi
Recruiting --> Terminated; Problems to recruit the needed number of patients in the planned time N=73 --> 5
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion, Adherence: BEACON: Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=1723, Completed, Sponsor: Bayer
N=73 --> 5 Active, not recruiting --> Completed
- | aspirin / Generic mfg.
Trial termination: Aspirin for Treatment of Multiple Sclerosis-Related Fatigue (clinicaltrials.gov) - Jan 16, 2014
P3, N=62, Terminated, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Terminated; Interim analysis indicated treatment unlikely effective;slow recruitment
- ||| Enrollment change: Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 16, 2014
P4, N=178, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; Interim analysis indicated treatment unlikely effective;slow recruitment N=226 --> 178
- | aspirin / Generic mfg.
Enrollment change: Aspirin for Treatment of Multiple Sclerosis-Related Fatigue (clinicaltrials.gov) - Jan 16, 2014
P3, N=62, Terminated, Sponsor: Mayo Clinic
N=226 --> 178 N=135 --> 62
- |||||| Enrollment open: INFORMS: FTY720 in Patients With Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jan 16, 2014
P3, N=940, Recruiting, Sponsor: Novartis Pharmaceuticals
N=135 --> 62 Active, not recruiting --> Recruiting
- ||| Enrollment closed: Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 16, 2014
P4, N=178, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Sativex (nabiximols) / Jazz
Trial completion: NS-MSS: Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity (clinicaltrials.gov) - Jan 16, 2014
P3, N=45, Completed, Sponsor: Almirall, S.A.
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Trial completion: Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (clinicaltrials.gov) - Jan 16, 2014
P4, N=54, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis (clinicaltrials.gov) - Jan 16, 2014
P=N/A, N=60, Completed, Sponsor: Nancy Hammond, MD
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Biomarker, Enrollment change: Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC (clinicaltrials.gov) - Jan 15, 2014
P=N/A, N=40, Recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed N=30 --> 40
- | Xeomin (incobotulinumtoxinA) / Merz Pharma
Enrollment open: Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients (clinicaltrials.gov) - Jan 15, 2014
P4, N=30, Recruiting, Sponsor: Multiple Sclerosis Center of Northeastern New York
N=30 --> 40 Not yet recruiting --> Recruiting
- Trial completion: Robot-assisted Gait Training in Multiple Sclerosis Subjects (clinicaltrials.gov) - Jan 14, 2014
P=N/A, N=60, Completed, Sponsor: University Hospital of Ferrara
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial suspension: Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects (clinicaltrials.gov) - Jan 14, 2014
P2, N=40, Suspended, Sponsor: University Hospital of Ferrara
Recruiting --> Completed Recruiting --> Suspended
- New P1/2 trial: Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=8, Recruiting, Sponsor: Germans Trias i Pujol Hospital
- | allogeneic human umbilical cord-derived mesenchymal stem cells (huMSC) / Medistem Panama
New P1/2 trial: Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 9, 2014
P1/2, N=20, Recruiting, Sponsor: Translational Biosciences
- ||| RNS60 / Revalesio
Trial initiation date: Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 7, 2014
P2, N=270, Not yet recruiting, Sponsor: Revalesio Corporation
Recruiting --> Suspended Initiation date: Feb 2014 --> Oct 2016
- fresolimumab (GC 1008) / Sanofi
Biomarker, Trial completion: Fresolimumab In Systemic Sclerosis (clinicaltrials.gov) - Jan 7, 2014
P1, N=18, Completed, Sponsor: Boston University
Initiation date: Feb 2014 --> Oct 2016 Recruiting --> Completed